Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary In-stent restenosis model
In-stent restenosis results primarily from neointimal hyperplasia. This study evaluated the efficacy and the optimal mode of administration of angiopeptin, a somatostatin analogue with antiproliferative activity, in a porcine coronary in-stent restenosis model. Forty pigs were randomly assigned to o...
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 1997-01, Vol.95 (2), p.449-454 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 454 |
|---|---|
| container_issue | 2 |
| container_start_page | 449 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 95 |
| creator | HONG, M. K KENT, K.M MEHRAN, R MINTZ, G. S TIO, F. O FOEGH, M CHIU WONG, S CATHAPERMAL, S. S LEON, M. B |
| description | In-stent restenosis results primarily from neointimal hyperplasia. This study evaluated the efficacy and the optimal mode of administration of angiopeptin, a somatostatin analogue with antiproliferative activity, in a porcine coronary in-stent restenosis model.
Forty pigs were randomly assigned to one of four groups (n = 10 per group): (1) controls receiving saline infusion at the site of stent implantation via a local delivery catheter, (2) local treatment group receiving one-time treatment (200 (micrograms angiopeptin) at the site of stent placement, (3) systemic treatment group receiving continuous angiopeptin over a 1-week period via a subcutaneous osmotic pump (200 micrograms/kg total dose) and (4) combined local and systemic treatment group. Then, one oversized Palmaz-Schatz stent (mean ratio of stent to artery diameters, 1.3:1) was implanted in the left anterior descending coronary artery. The degree of neointimal reaction was evaluated 4 weeks later by angiography (maximal percent diameter stenosis), intravascular ultrasound (total in-stent neointimal volume), and histology (maximal area stenosis). Systemic treatment produced the least neointimal hyperplasia and significantly reduced in-stent restenosis compared with the control group by all end points, despite similar degrees of injury. Angiography showed 25 +/- 17% versus 50 +/- 17% diameter stenosis in the systemic angiopeptin group versus the control group (P < .0001), intravascular ultrasound revealed 23 +/- 10 versus 58 +/- 27 mm3 neointimal volume in the systemic angiopeptin versus control group (P = .0002), and histology showed 41 +/- 16% versus 69 +/- 18% area stenosis (P = .0016) in the systemic angiopeptin versus control group. Plasma angiopeptin levels revealed rapid clearance (within 6 hours) after local therapy, whereas the levels persisted for up to 2 weeks in the systemic group.
This study shows that continuous subcutaneous treatment with angiopeptin after stent implantation significantly reduces in-stent restenosis by inhibiting neointimal hyperplasia. |
| doi_str_mv | 10.1161/01.cir.95.2.449 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78813352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18605266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-9cdc44e47a68963edd8e0cb314a1bba0ee01767c96abb0982b8eb630d5808a8d3</originalsourceid><addsrcrecordid>eNpdkU2LFDEQhoMo67h69iQEEW_dm-9OjjL4MbAgiJ5Dkq5Zs3QnbdJ9mL_grzbDDHuQHIrifeqlKi9CbynpKVX0jtA-xNIb2bNeCPMM7ahkohOSm-doRwgx3cAZe4le1frYWsUHeYNuDCFaKL5Df_c5rTFteau4bj5sq0twblx6iHmBpYl4LeDWGdKKa3xI8RiDS-t0wgXGLUDFbSI2l9lN-PdpgbJMrkaH26TDSy4hJsAhl5xcOeFD6up69ipwrrnGiuc8wvQavTi6qcKba71Fv758_rn_1t1__3rYf7rvgtBk7UwYgxAgBqe0URzGUQMJnlPhqPeOABA6qCEY5bwnRjOvwStORqmJdnrkt-jjxXcp-c_WlrBzrAGm6XK5HbSmnEvWwPf_gY95K6ntZhllSio90AbdXaBQcq0FjnYp7SfKyVJizxFZQu3-8MMaaZltEbWJd1fbzc8wPvHXTJr-4aq7Gtx0LC6FWJ8wJkV7hP8DE36dtg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212656871</pqid></control><display><type>article</type><title>Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary In-stent restenosis model</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>HONG, M. K ; KENT, K.M ; MEHRAN, R ; MINTZ, G. S ; TIO, F. O ; FOEGH, M ; CHIU WONG, S ; CATHAPERMAL, S. S ; LEON, M. B</creator><creatorcontrib>HONG, M. K ; KENT, K.M ; MEHRAN, R ; MINTZ, G. S ; TIO, F. O ; FOEGH, M ; CHIU WONG, S ; CATHAPERMAL, S. S ; LEON, M. B</creatorcontrib><description>In-stent restenosis results primarily from neointimal hyperplasia. This study evaluated the efficacy and the optimal mode of administration of angiopeptin, a somatostatin analogue with antiproliferative activity, in a porcine coronary in-stent restenosis model.
Forty pigs were randomly assigned to one of four groups (n = 10 per group): (1) controls receiving saline infusion at the site of stent implantation via a local delivery catheter, (2) local treatment group receiving one-time treatment (200 (micrograms angiopeptin) at the site of stent placement, (3) systemic treatment group receiving continuous angiopeptin over a 1-week period via a subcutaneous osmotic pump (200 micrograms/kg total dose) and (4) combined local and systemic treatment group. Then, one oversized Palmaz-Schatz stent (mean ratio of stent to artery diameters, 1.3:1) was implanted in the left anterior descending coronary artery. The degree of neointimal reaction was evaluated 4 weeks later by angiography (maximal percent diameter stenosis), intravascular ultrasound (total in-stent neointimal volume), and histology (maximal area stenosis). Systemic treatment produced the least neointimal hyperplasia and significantly reduced in-stent restenosis compared with the control group by all end points, despite similar degrees of injury. Angiography showed 25 +/- 17% versus 50 +/- 17% diameter stenosis in the systemic angiopeptin group versus the control group (P < .0001), intravascular ultrasound revealed 23 +/- 10 versus 58 +/- 27 mm3 neointimal volume in the systemic angiopeptin versus control group (P = .0002), and histology showed 41 +/- 16% versus 69 +/- 18% area stenosis (P = .0016) in the systemic angiopeptin versus control group. Plasma angiopeptin levels revealed rapid clearance (within 6 hours) after local therapy, whereas the levels persisted for up to 2 weeks in the systemic group.
This study shows that continuous subcutaneous treatment with angiopeptin after stent implantation significantly reduces in-stent restenosis by inhibiting neointimal hyperplasia.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.cir.95.2.449</identifier><identifier>PMID: 9008463</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Animals ; Biological and medical sciences ; Cardiovascular Agents - blood ; Cardiovascular Agents - therapeutic use ; Cardiovascular system ; Coronary Angiography ; Coronary Disease - blood ; Coronary Disease - pathology ; Coronary Disease - therapy ; Hyperplasia ; Injections, Subcutaneous ; Medical sciences ; Oligopeptides - blood ; Oligopeptides - therapeutic use ; Pharmacology. Drug treatments ; Recurrence ; Somatostatin - analogs & derivatives ; Somatostatin - blood ; Somatostatin - therapeutic use ; Stents ; Swine ; Tunica Intima - drug effects ; Tunica Intima - pathology ; Ultrasonography, Interventional ; Vascular wall</subject><ispartof>Circulation (New York, N.Y.), 1997-01, Vol.95 (2), p.449-454</ispartof><rights>1997 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Jan 21, 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-9cdc44e47a68963edd8e0cb314a1bba0ee01767c96abb0982b8eb630d5808a8d3</citedby><cites>FETCH-LOGICAL-c480t-9cdc44e47a68963edd8e0cb314a1bba0ee01767c96abb0982b8eb630d5808a8d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3686,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2545450$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9008463$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HONG, M. K</creatorcontrib><creatorcontrib>KENT, K.M</creatorcontrib><creatorcontrib>MEHRAN, R</creatorcontrib><creatorcontrib>MINTZ, G. S</creatorcontrib><creatorcontrib>TIO, F. O</creatorcontrib><creatorcontrib>FOEGH, M</creatorcontrib><creatorcontrib>CHIU WONG, S</creatorcontrib><creatorcontrib>CATHAPERMAL, S. S</creatorcontrib><creatorcontrib>LEON, M. B</creatorcontrib><title>Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary In-stent restenosis model</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>In-stent restenosis results primarily from neointimal hyperplasia. This study evaluated the efficacy and the optimal mode of administration of angiopeptin, a somatostatin analogue with antiproliferative activity, in a porcine coronary in-stent restenosis model.
Forty pigs were randomly assigned to one of four groups (n = 10 per group): (1) controls receiving saline infusion at the site of stent implantation via a local delivery catheter, (2) local treatment group receiving one-time treatment (200 (micrograms angiopeptin) at the site of stent placement, (3) systemic treatment group receiving continuous angiopeptin over a 1-week period via a subcutaneous osmotic pump (200 micrograms/kg total dose) and (4) combined local and systemic treatment group. Then, one oversized Palmaz-Schatz stent (mean ratio of stent to artery diameters, 1.3:1) was implanted in the left anterior descending coronary artery. The degree of neointimal reaction was evaluated 4 weeks later by angiography (maximal percent diameter stenosis), intravascular ultrasound (total in-stent neointimal volume), and histology (maximal area stenosis). Systemic treatment produced the least neointimal hyperplasia and significantly reduced in-stent restenosis compared with the control group by all end points, despite similar degrees of injury. Angiography showed 25 +/- 17% versus 50 +/- 17% diameter stenosis in the systemic angiopeptin group versus the control group (P < .0001), intravascular ultrasound revealed 23 +/- 10 versus 58 +/- 27 mm3 neointimal volume in the systemic angiopeptin versus control group (P = .0002), and histology showed 41 +/- 16% versus 69 +/- 18% area stenosis (P = .0016) in the systemic angiopeptin versus control group. Plasma angiopeptin levels revealed rapid clearance (within 6 hours) after local therapy, whereas the levels persisted for up to 2 weeks in the systemic group.
This study shows that continuous subcutaneous treatment with angiopeptin after stent implantation significantly reduces in-stent restenosis by inhibiting neointimal hyperplasia.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular Agents - blood</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Cardiovascular system</subject><subject>Coronary Angiography</subject><subject>Coronary Disease - blood</subject><subject>Coronary Disease - pathology</subject><subject>Coronary Disease - therapy</subject><subject>Hyperplasia</subject><subject>Injections, Subcutaneous</subject><subject>Medical sciences</subject><subject>Oligopeptides - blood</subject><subject>Oligopeptides - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Recurrence</subject><subject>Somatostatin - analogs & derivatives</subject><subject>Somatostatin - blood</subject><subject>Somatostatin - therapeutic use</subject><subject>Stents</subject><subject>Swine</subject><subject>Tunica Intima - drug effects</subject><subject>Tunica Intima - pathology</subject><subject>Ultrasonography, Interventional</subject><subject>Vascular wall</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU2LFDEQhoMo67h69iQEEW_dm-9OjjL4MbAgiJ5Dkq5Zs3QnbdJ9mL_grzbDDHuQHIrifeqlKi9CbynpKVX0jtA-xNIb2bNeCPMM7ahkohOSm-doRwgx3cAZe4le1frYWsUHeYNuDCFaKL5Df_c5rTFteau4bj5sq0twblx6iHmBpYl4LeDWGdKKa3xI8RiDS-t0wgXGLUDFbSI2l9lN-PdpgbJMrkaH26TDSy4hJsAhl5xcOeFD6up69ipwrrnGiuc8wvQavTi6qcKba71Fv758_rn_1t1__3rYf7rvgtBk7UwYgxAgBqe0URzGUQMJnlPhqPeOABA6qCEY5bwnRjOvwStORqmJdnrkt-jjxXcp-c_WlrBzrAGm6XK5HbSmnEvWwPf_gY95K6ntZhllSio90AbdXaBQcq0FjnYp7SfKyVJizxFZQu3-8MMaaZltEbWJd1fbzc8wPvHXTJr-4aq7Gtx0LC6FWJ8wJkV7hP8DE36dtg</recordid><startdate>19970121</startdate><enddate>19970121</enddate><creator>HONG, M. K</creator><creator>KENT, K.M</creator><creator>MEHRAN, R</creator><creator>MINTZ, G. S</creator><creator>TIO, F. O</creator><creator>FOEGH, M</creator><creator>CHIU WONG, S</creator><creator>CATHAPERMAL, S. S</creator><creator>LEON, M. B</creator><general>Lippincott Williams & Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>19970121</creationdate><title>Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary In-stent restenosis model</title><author>HONG, M. K ; KENT, K.M ; MEHRAN, R ; MINTZ, G. S ; TIO, F. O ; FOEGH, M ; CHIU WONG, S ; CATHAPERMAL, S. S ; LEON, M. B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-9cdc44e47a68963edd8e0cb314a1bba0ee01767c96abb0982b8eb630d5808a8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular Agents - blood</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Cardiovascular system</topic><topic>Coronary Angiography</topic><topic>Coronary Disease - blood</topic><topic>Coronary Disease - pathology</topic><topic>Coronary Disease - therapy</topic><topic>Hyperplasia</topic><topic>Injections, Subcutaneous</topic><topic>Medical sciences</topic><topic>Oligopeptides - blood</topic><topic>Oligopeptides - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Recurrence</topic><topic>Somatostatin - analogs & derivatives</topic><topic>Somatostatin - blood</topic><topic>Somatostatin - therapeutic use</topic><topic>Stents</topic><topic>Swine</topic><topic>Tunica Intima - drug effects</topic><topic>Tunica Intima - pathology</topic><topic>Ultrasonography, Interventional</topic><topic>Vascular wall</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HONG, M. K</creatorcontrib><creatorcontrib>KENT, K.M</creatorcontrib><creatorcontrib>MEHRAN, R</creatorcontrib><creatorcontrib>MINTZ, G. S</creatorcontrib><creatorcontrib>TIO, F. O</creatorcontrib><creatorcontrib>FOEGH, M</creatorcontrib><creatorcontrib>CHIU WONG, S</creatorcontrib><creatorcontrib>CATHAPERMAL, S. S</creatorcontrib><creatorcontrib>LEON, M. B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HONG, M. K</au><au>KENT, K.M</au><au>MEHRAN, R</au><au>MINTZ, G. S</au><au>TIO, F. O</au><au>FOEGH, M</au><au>CHIU WONG, S</au><au>CATHAPERMAL, S. S</au><au>LEON, M. B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary In-stent restenosis model</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>1997-01-21</date><risdate>1997</risdate><volume>95</volume><issue>2</issue><spage>449</spage><epage>454</epage><pages>449-454</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>In-stent restenosis results primarily from neointimal hyperplasia. This study evaluated the efficacy and the optimal mode of administration of angiopeptin, a somatostatin analogue with antiproliferative activity, in a porcine coronary in-stent restenosis model.
Forty pigs were randomly assigned to one of four groups (n = 10 per group): (1) controls receiving saline infusion at the site of stent implantation via a local delivery catheter, (2) local treatment group receiving one-time treatment (200 (micrograms angiopeptin) at the site of stent placement, (3) systemic treatment group receiving continuous angiopeptin over a 1-week period via a subcutaneous osmotic pump (200 micrograms/kg total dose) and (4) combined local and systemic treatment group. Then, one oversized Palmaz-Schatz stent (mean ratio of stent to artery diameters, 1.3:1) was implanted in the left anterior descending coronary artery. The degree of neointimal reaction was evaluated 4 weeks later by angiography (maximal percent diameter stenosis), intravascular ultrasound (total in-stent neointimal volume), and histology (maximal area stenosis). Systemic treatment produced the least neointimal hyperplasia and significantly reduced in-stent restenosis compared with the control group by all end points, despite similar degrees of injury. Angiography showed 25 +/- 17% versus 50 +/- 17% diameter stenosis in the systemic angiopeptin group versus the control group (P < .0001), intravascular ultrasound revealed 23 +/- 10 versus 58 +/- 27 mm3 neointimal volume in the systemic angiopeptin versus control group (P = .0002), and histology showed 41 +/- 16% versus 69 +/- 18% area stenosis (P = .0016) in the systemic angiopeptin versus control group. Plasma angiopeptin levels revealed rapid clearance (within 6 hours) after local therapy, whereas the levels persisted for up to 2 weeks in the systemic group.
This study shows that continuous subcutaneous treatment with angiopeptin after stent implantation significantly reduces in-stent restenosis by inhibiting neointimal hyperplasia.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>9008463</pmid><doi>10.1161/01.cir.95.2.449</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 1997-01, Vol.95 (2), p.449-454 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78813352 |
| source | MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Animals Biological and medical sciences Cardiovascular Agents - blood Cardiovascular Agents - therapeutic use Cardiovascular system Coronary Angiography Coronary Disease - blood Coronary Disease - pathology Coronary Disease - therapy Hyperplasia Injections, Subcutaneous Medical sciences Oligopeptides - blood Oligopeptides - therapeutic use Pharmacology. Drug treatments Recurrence Somatostatin - analogs & derivatives Somatostatin - blood Somatostatin - therapeutic use Stents Swine Tunica Intima - drug effects Tunica Intima - pathology Ultrasonography, Interventional Vascular wall |
| title | Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary In-stent restenosis model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T19%3A13%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Continuous%20subcutaneous%20angiopeptin%20treatment%20significantly%20reduces%20neointimal%20hyperplasia%20in%20a%20porcine%20coronary%20In-stent%20restenosis%20model&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=HONG,%20M.%20K&rft.date=1997-01-21&rft.volume=95&rft.issue=2&rft.spage=449&rft.epage=454&rft.pages=449-454&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.cir.95.2.449&rft_dat=%3Cproquest_cross%3E18605266%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212656871&rft_id=info:pmid/9008463&rfr_iscdi=true |